Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
Rev. bras. hematol. hemoter
;
36(1): 54-59, Jan-Feb/2014.
Article
in English
| LILACS
| ID: lil-703702
ABSTRACT
Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Protein-Tyrosine Kinases
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Fusion Proteins, bcr-abl
Type of study:
Practice guideline
Limits:
Humans
Language:
English
Journal:
Rev. bras. hematol. hemoter
Journal subject:
Hematology
Year:
2014
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Hospital de Clínicas de Porto Alegre/BR
/
Instituto Nacional de Câncer/BR
/
Universidade Estadual de Campinas/BR
Similar
MEDLINE
...
LILACS
LIS